Advancing Automation with AI Technologies for Precise Cancer Care Treatment – A fireside chat with GE
Here at Mirada Medical, we are excited to continue to grow our relationship with GE Healthcare. We share a commitment to delivering impactful solutions to cancer care teams so that they can take better care of their patients. Our first step was to integrate our RTx solution into the GE Healthcare AW Workstation and AW Server to enable enhanced cancer visualization and diagnostic capabilities.At ASTRO 2021 our CEO John DeVries and GE Healthcare’s Saad Sirohey, GM, Global MICT Clinical Applications, took time out to discuss what the future might look like for the partnership. Watch now to learn about new techniques for advancing automation with AI technology for precise cancer care treatment.
Apposite Capital Makes Further Investment in Mirada Medical to Advance Precision Cancer Care
London, UK – 8th June 2022. Apposite Capital, the healthcare specialist private equity investor, today announces that it has made a further investment in Mirada Medical, a world leader in precision imaging software and image guided tools for cancer care. This investment brings total investment in Mirada since Apposite first invested in 2019 to c. $20m of new growth capital.
Mirada has globally recognized capabilities in software for quantitative image analysis and disease characterization used to diagnose cancer and guide delivery of radiation-based treatments. Mirada’s software is currently used in over 2,000 hospitals globally and sold directly to hospitals as well as through strategic partnerships with the world’s leading imaging and radiotherapy companies, including GE, Boston Scientific, Canon, Philips, Varian and Change Healthcare.
For example, Mirada has formed a global collaboration with GE Healthcare to improve outcomes for cancer patients by integrating Mirada’s advanced automation and AI technologies to enable faster, more consistent and more precise cancer radiotherapy treatment.
Additionally, Mirada has partnered with Boston Scientific to develop and commercialize Simplicit90Y™, a software product that enables personalization of dosimetry planning for TheraSphere™, a radiation-based cancer treatment that utilizes microscopic radioactive glass microspheres. The precision dosimetry capabilities enabled through Mirada’s software have been proven in clinical trials to dramatically improve response rate, survival, and the proportion of patients that become eligible for potentially curative surgical treatments.
Sam Gray, Managing Partner of Apposite Capital and a member of Mirada’s Board of Directors, commented: “Mirada operates at the intersection of a number of high growth themes in healthcare, including the increasing adoption of AI in medical imaging and analysis, increased use of precision tools for enabling higher dose radiation treatments, and the development of novel interventional oncology and radiopharmaceutical modalities. We are delighted to back the world-class management of the company, now represented on both sides of the Atlantic, as they continue to commercialize and develop these solutions.”
Jon DeVries, CEO of Mirada, also commented: “Mirada is thrilled that Apposite believes strongly enough in our mission to double down on their investment. Everyone’s cancer is unique to them, and our vision is to transform cancer care by delivering personalized, image-guided cancer therapies to patients everywhere. Mirada delivers world-class technologies such as the first FDA cleared AI application for radiation oncology and solutions proven in clinical trials to improve patient outcomes. The funding provided by Apposite will enable us to continue to grow and deliver transformative solutions to physicians.”
– end –
Tel: +44(0) 20 3475 1710
About Apposite Capital
Apposite Capital is an independent investment firm focused exclusively on healthcare. It backs companies operating in health and social care, medtech & medical products, pharmaceuticals & life sciences and digital health.
Apposite Capital operates at the small end of the private equity market, providing both capital and expertise to those businesses offering ‘disruptive’ models that aim to improve or reduce the cost of care provision and which have the potential to become market leaders.
Apposite has an in-depth sector knowledge covering key aspects of the healthcare industry internationally, an exceptional network and an entrepreneurial mindset which it applies to drive the growth of its portfolio companies both organically and inorganically.
Apposite Capital was established in 2006 and is headquartered in London, UK.
Mirada Medical is a leading international provider of image analysis software for radiology and oncology. It extracts information from image data to help physicians deliver personalized and precise image-guided cancer treatments. The company drives innovations that work in harmony across three specialties: diagnostic imaging, technologies for external beam radiotherapy (RT) applications, and treatment plans for interventional procedures.
The company specializes in simplifying technically complex image processing tasks, allowing clinicians to diagnose disease, assess response to treatment, and plan radiation therapy or surgical intervention more confidently. Mirada’s advanced technology products are available throughout the world under its own brand, and on an OEM basis through a select number of the world’s leading healthcare companies.
Mirada recognized as a Top 100 Digital Health Company by the DIT
New initiative that recognizes the UK’s leading digital health organizations
By Hugh Bettesworth, CEO, Mirada MedicalI am excited to announce that Mirada Medial has been recognized as one of the top 100 UK digital healthcare companies by the Department for International Trade (DIT). We have been included in the DIT’s prestigious ‘First 100 Playbook’ in recognition of our work driving digital innovation across image diagnostics and treatment planning services.Digital Health is critical to solve the challenges facing healthcareThe global health sector has been under exceptional pressure over the last year. However, the pandemic has also forced innovation and advances in digital health initiatives. Many cancer care services have been postponed because of COVID. With a treatment backlog on our hands, digital tools such as Automation and Artificial Intelligence (AI) have a critical role to play. The widespread use of AI technology enables healthcare teams to treat more patients, improving cancer care and tackling the backlog. Over the last year, Mirada has focused on getting this technology into the hands of cancer care clinicians. As a result of our work bringing digital technology to the NHS front line, the DIT has recognized Mirada’s contribution in its ‘First 100 playbook’ initiative.The First 100 PlaybookThe playbook is a new initiative that recognizes the UK’s leading digital health organizations; those who are not just leaders in their field but in particular those who set new standards, pioneer new inventions and progress the state of the art. It involves a rigorous judging process and we had to demonstrate our commitment to international expansion as well as our responsiveness to the market.Most of all, we had to show the uniqueness of our offering, and demonstrate our ability to positively represent the UK journey and the direction of digital health. The First 100 Playbook is only awarded to the top 100 digital health companies in the UK. And we made it. To say we are proud is an understatement. To borrow the DIT’s motto, we think that ‘Innovation is Great’. Many thanks to my colleagues, customers, and partners whose invaluable help has made this happen.Download the ‘First 100 Playbook’ – https://bit.ly/3tUkflK – to see our listing!#AI in #healthcare
Pioneering Personalized Cancer Care
“Everybody’s cancer is unique, requiring a personalized and precise treatment,” says Jon DeVries, CEO of Mirada Medical. An innovative application provider of image analysis software for radiology and oncology, Mirada Medical extracts information from image data to help physicians deliver personalized and precise image-guided cancer treatments. The company drives innovations that work in harmony across three specialties; diagnostic imaging, technologies for external beam radiotherapy (RT) applications, and treatment plans for interventional procedures.
RefleXion Announces Licensing Agreement with Mirada Medical to Advance
Personalized Cancer Treatment
Rapid, adaptive radiotherapy treatment plans hold potential to reduce toxicity and improvepatient outcomes
HAYWARD, Calif., July 7, 2022
RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT)* for all stages of cancer, todayannounced a non-exclusive, worldwide licensing agreement with Mirada Medical. The agreement allows for the integration of Mirada’s RegEngineÔ image registration algorithms into the RefleXionÒ X1 treatment planning software. The algorithms align patient anatomy betweendifferent imaging modalities or between radiotherapy treatments.
“Day-of-treatment modifications, called adaptive radiotherapy, are critical for responding tochanges in patient anatomy that occur as a result of cancer treatment, and to lowering toxicity toimprove outcomes,” said Thorsten Melcher, Ph.D., chief business officer at RefleXion. “Inchallenging patients, such as those with metastatic disease where more than one tumor may betreated, adaptation requires robust tools such as Mirada’s sophisticated RegEngine software, sothat clinicians can quickly assess patient anatomy and, in the future their biology, to implementchanges to the treatment plan.
“Mirada’s extensive industry experience and development expertise were key factors in ourdecision to pursue this agreement,” continued Melcher.Image registration is a complex series of algorithms that align the images of a patient’s anatomytaken at different points in time and using different imaging modalities. For radiation oncology,where millimeters matter in order to preserve healthy tissue, registration of the tumor target tobe treated, as well as nearby anatomy to avoid, is critical. Precise targeting may also result inlowering toxicity, thereby improving outcomes for patients.
BgRT is designed to one day overcome the technical limitations of existing radiotherapyapproaches by using a PET radiotracer to create a unified motion management solution for oneor multiple tumors. As the PET tracer binds to tumor cells, it produces emissions that signal thecancer’s location. BgRT uses this real-time biological information to deliver a tracked radiationdose to the cancer. Integrating RegEngine into BgRT will allow clinicians to rapidly adapt thedaily treatment plan by precisely registering images and image components crucial for treatmentplanning and dose calculation.
A difficult challenge occurs when the frames of reference of the images are similar, but thepatient’s anatomy has changed from biological processes, such as breathing or digestion, orchanges in position during the imaging procedures. To assist clinicians in accounting for thesechanges, RegEngine “warps” or “deforms” the images pixel by pixel, a process calleddeformable image registration.
“Our relationship with RefleXion is another example of our ability to work with cutting edgeoncology companies,” said Jon DeVries, CEO at Mirada. “RefleXion’s biology-guidedradiotherapy has the potential to offer a new treatment option for patients with all stages ofcancer, and we are excited and proud to have RegEngine selected as a key component of thetreatment planning process in this exciting novel technology.”
About Mirada MedicalMirada Medical specializes in simplifying technically complex image processing tasks, allowingclinicians to diagnose disease, assess response to treatment, and plan radiation therapy orsurgical intervention more confidently. Mirada launched the first commercial software applicationto register positron emission tomography (PET) and computed tomography (CT) images in 1999and has since developed into a world leader in image registration.
About RefleXion MedicalRefleXion is a privately-held company developing the first biology-guided radiotherapy system,a significant change in strategy from single tumor therapy to the ability to one day treat multipletumors in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared forthe delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) andintensity modulated radiotherapy (IMRT). The company is also developing BgRT, whichincorporates positron-emission tomography (PET) imaging data to enable tumors tocontinuously signal their location. The BgRT technology will synchronize these data with thelinear accelerator to direct radiotherapy to tumors with subsecond latency.*The RefleXion X1 is cleared for SBRT/SRS/IMRT. BgRT is pending regulatory review and isnot commercially available.
# # #
Media Contacts:RefleXionAmy Cookacook@reflexion.com925-200-212